Results 1 to 10 of about 342,462 (260)
A general evidence-based sequence variant control limit for recombinant therapeutic protein development [PDF]
mAbs, 2020 Sequence variants (SVs) resulting from unintended amino acid substitutions in recombinant therapeutic proteins have increasingly gained attention from both regulatory agencies and the biopharmaceutical industry given their potential impact on efficacy ...
Aming Zhang +6 more
doaj +4 more sources
mRNA and Synthesis-Based Therapeutic Proteins: A Non-Recombinant Affordable Option
Biologics, 2023 Recombinant technology has been around for nearly three quarters of a century and has revolutionized protein therapy. However, the cost of developing recombinant therapeutic proteins and the manufacturing infrastructure keeps their cost unaffordable for ...
Sarfaraz K. Niazi, Matthias Magoola
doaj +3 more sources
Therapeutic recombinant protein production in plants: Challenges and opportunities
Plants, People, Planet, 2020 Societal Impact Statement Therapeutic protein production in plants is an area of great potential for increasing and improving the production of proteins for the treatment or prevention of disease in humans and other animals.
Matthew J. B. Burnett, Angela C. Burnett
doaj +2 more sources
Frontiers in Bioengineering and Biotechnology, 2022 Recombinant therapeutic proteins (RTPs) are important parts of biopharmaceuticals. Chinese hamster ovary cells (CHO) have become the main cell hosts for the production of most RTPs approved for marketing because of their high-density suspension growth ...
Zheng-Mei Li +7 more
doaj +3 more sources
Journal of Biological EngineeringBackgroud Genetically engineered photosynthetic microorganisms have been proposed as a therapeutic approach for the localized delivery of oxygen and recombinant proteins to tissues in various pathological conditions.
Felipe Carvajal +4 more
doaj +2 more sources
Molecular Therapy: Oncolytics, 2023 CD47 and its receptor signal regulatory protein α (SIRPα) act as a dominant antiphagocytic, “don’t eat me” signal. Recent studies reveal CD24 as a novel target for cancer immunotherapy by macrophages in ovarian cancer and breast cancer.
Yun Yang +10 more
doaj +1 more source
Serum-Free Medium for Recombinant Protein Expression in Chinese Hamster Ovary Cells
Frontiers in Bioengineering and Biotechnology, 2021 At present, nearly 70% of recombinant therapeutic proteins (RTPs) are produced by Chinese hamster ovary (CHO) cells, and serum-free medium (SFM) is necessary for their culture to produce RTPs.
Weifeng Li +4 more
doaj +1 more source
Frontiers in Bioengineering and Biotechnology, 2022 In recent years, mammalian cells have become the primary host cells for the production of recombinant therapeutic proteins (RTPs). Despite that the expression of RTPs in mammalian cells can be improved by directly optimizing or engineering the expression
Mian Wei +4 more
doaj +1 more source
Screening Strategies for High-Yield Chinese Hamster Ovary Cell Clones
Frontiers in Bioengineering and Biotechnology, 2022 Chinese hamster ovary (CHO) cells are by far the most commonly used mammalian expression system for recombinant expression of therapeutic proteins in the pharmaceutical industry.
Wenwen Yang +8 more
doaj +1 more source
Applied Sciences, 2021 The enhancement of recombinant therapeutic protein production in mammalian cell culture has been regarded as an important issue in the biopharmaceutical industry.
Hyeonjin Cha, Ju-Hyun Park
doaj +1 more source